13
ASCO Resource Levels
Strength of
Recommendation Basic Limited Enhanced Maximal
Palliative
care
Single
agent
fluoropy-
rimidine
if
available,
if not,
referral
to other
facility
Doublet
chemotherapy
Doublet
chemotherapy
± anti-VEGF
(bevacizumab)
Strong
Moderate
(chemotherapy +
anti-VEGF)
N/A N/A Doublet
chemotherapy
± anti-VEGF
(bevacizumab)
Strong
Moderate
(chemotherapy +
anti-VEGF)
N/A N/A Doublet
chemotherapy
± anti-EGFR or
doublet
chemotherapy
± anti-VEGF
(bevacizumab)
Strong
(chemotherapy)
Moderate
(chemotherapy ±
anti-EGFR)
Moderate
(chemotherapy ±
anti-VEGF)
N/A N/A Triplet
chemotherapy
Triplet
chemotherapy
± anti-VEGF
(bevacizumab)
Strong
(chemotherapy)
Moderate
(chemotherapy +
anti-VEGF)
N/A Single agent
fluoropyrimidine
Single agent
fluoropyrimidine
± anti-VEGF
(bevacizumab)
Strong
(chemotherapy)
Moderate
(chemotherapy +
anti-VEGF)
N/A N/A N/A Anti-EGFR
monotherapy
Moderate
Supportive care only Strong
